Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial</title><author><name sortKey="Ribi, Karin" sort="Ribi, Karin" uniqKey="Ribi K" first="Karin" last="Ribi">Karin Ribi</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Luo, Weixiu" sort="Luo, Weixiu" uniqKey="Luo W" first="Weixiu" last="Luo">Weixiu Luo</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Bernhard, Jurg" sort="Bernhard, Jurg" uniqKey="Bernhard J" first="Jürg" last="Bernhard">Jürg Bernhard</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Francis, Prudence A" sort="Francis, Prudence A" uniqKey="Francis P" first="Prudence A." last="Francis">Prudence A. Francis</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Burstein, Harold J" sort="Burstein, Harold J" uniqKey="Burstein H" first="Harold J." last="Burstein">Harold J. Burstein</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Ciruelos, Eva" sort="Ciruelos, Eva" uniqKey="Ciruelos E" first="Eva" last="Ciruelos">Eva Ciruelos</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Bellet, Meritxell" sort="Bellet, Meritxell" uniqKey="Bellet M" first="Meritxell" last="Bellet">Meritxell Bellet</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Pavesi, Lorenzo" sort="Pavesi, Lorenzo" uniqKey="Pavesi L" first="Lorenzo" last="Pavesi">Lorenzo Pavesi</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Lluch, Ana" sort="Lluch, Ana" uniqKey="Lluch A" first="Ana" last="Lluch">Ana Lluch</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Visini, Marilena" sort="Visini, Marilena" uniqKey="Visini M" first="Marilena" last="Visini">Marilena Visini</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Parmar, Vani" sort="Parmar, Vani" uniqKey="Parmar V" first="Vani" last="Parmar">Vani Parmar</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Tondini, Carlo" sort="Tondini, Carlo" uniqKey="Tondini C" first="Carlo" last="Tondini">Carlo Tondini</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Kerbrat, Pierre" sort="Kerbrat, Pierre" uniqKey="Kerbrat P" first="Pierre" last="Kerbrat">Pierre Kerbrat</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Perell, Antonia" sort="Perell, Antonia" uniqKey="Perell A" first="Antonia" last="Perell">Antonia Perell</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Neven, Patrick" sort="Neven, Patrick" uniqKey="Neven P" first="Patrick" last="Neven">Patrick Neven</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Torres, Roberto" sort="Torres, Roberto" uniqKey="Torres R" first="Roberto" last="Torres">Roberto Torres</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Lombardi, Davide" sort="Lombardi, Davide" uniqKey="Lombardi D" first="Davide" last="Lombardi">Davide Lombardi</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Puglisi, Fabio" sort="Puglisi, Fabio" uniqKey="Puglisi F" first="Fabio" last="Puglisi">Fabio Puglisi</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Karlsson, Per" sort="Karlsson, Per" uniqKey="Karlsson P" first="Per" last="Karlsson">Per Karlsson</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Ruhstaller, Thomas" sort="Ruhstaller, Thomas" uniqKey="Ruhstaller T" first="Thomas" last="Ruhstaller">Thomas Ruhstaller</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Colleoni, Marco" sort="Colleoni, Marco" uniqKey="Colleoni M" first="Marco" last="Colleoni">Marco Colleoni</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Goldhirsch, Aron" sort="Goldhirsch, Aron" uniqKey="Goldhirsch A" first="Aron" last="Goldhirsch">Aron Goldhirsch</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Price, Karen N" sort="Price, Karen N" uniqKey="Price K" first="Karen N." last="Price">Karen N. Price</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Gelber, Richard D" sort="Gelber, Richard D" uniqKey="Gelber R" first="Richard D." last="Gelber">Richard D. Gelber</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Regan, Meredith M" sort="Regan, Meredith M" uniqKey="Regan M" first="Meredith M." last="Regan">Meredith M. Regan</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Fleming, Gini F" sort="Fleming, Gini F" uniqKey="Fleming G" first="Gini F." last="Fleming">Gini F. Fleming</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27022111</idno><idno type="pmc">4872319</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872319</idno><idno type="RBID">PMC:4872319</idno><idno type="doi">10.1200/JCO.2015.64.8675</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000463</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000463</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial</title><author><name sortKey="Ribi, Karin" sort="Ribi, Karin" uniqKey="Ribi K" first="Karin" last="Ribi">Karin Ribi</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Luo, Weixiu" sort="Luo, Weixiu" uniqKey="Luo W" first="Weixiu" last="Luo">Weixiu Luo</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Bernhard, Jurg" sort="Bernhard, Jurg" uniqKey="Bernhard J" first="Jürg" last="Bernhard">Jürg Bernhard</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Francis, Prudence A" sort="Francis, Prudence A" uniqKey="Francis P" first="Prudence A." last="Francis">Prudence A. Francis</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Burstein, Harold J" sort="Burstein, Harold J" uniqKey="Burstein H" first="Harold J." last="Burstein">Harold J. Burstein</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Ciruelos, Eva" sort="Ciruelos, Eva" uniqKey="Ciruelos E" first="Eva" last="Ciruelos">Eva Ciruelos</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Bellet, Meritxell" sort="Bellet, Meritxell" uniqKey="Bellet M" first="Meritxell" last="Bellet">Meritxell Bellet</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Pavesi, Lorenzo" sort="Pavesi, Lorenzo" uniqKey="Pavesi L" first="Lorenzo" last="Pavesi">Lorenzo Pavesi</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Lluch, Ana" sort="Lluch, Ana" uniqKey="Lluch A" first="Ana" last="Lluch">Ana Lluch</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Visini, Marilena" sort="Visini, Marilena" uniqKey="Visini M" first="Marilena" last="Visini">Marilena Visini</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Parmar, Vani" sort="Parmar, Vani" uniqKey="Parmar V" first="Vani" last="Parmar">Vani Parmar</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Tondini, Carlo" sort="Tondini, Carlo" uniqKey="Tondini C" first="Carlo" last="Tondini">Carlo Tondini</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Kerbrat, Pierre" sort="Kerbrat, Pierre" uniqKey="Kerbrat P" first="Pierre" last="Kerbrat">Pierre Kerbrat</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Perell, Antonia" sort="Perell, Antonia" uniqKey="Perell A" first="Antonia" last="Perell">Antonia Perell</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Neven, Patrick" sort="Neven, Patrick" uniqKey="Neven P" first="Patrick" last="Neven">Patrick Neven</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Torres, Roberto" sort="Torres, Roberto" uniqKey="Torres R" first="Roberto" last="Torres">Roberto Torres</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Lombardi, Davide" sort="Lombardi, Davide" uniqKey="Lombardi D" first="Davide" last="Lombardi">Davide Lombardi</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Puglisi, Fabio" sort="Puglisi, Fabio" uniqKey="Puglisi F" first="Fabio" last="Puglisi">Fabio Puglisi</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Karlsson, Per" sort="Karlsson, Per" uniqKey="Karlsson P" first="Per" last="Karlsson">Per Karlsson</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Ruhstaller, Thomas" sort="Ruhstaller, Thomas" uniqKey="Ruhstaller T" first="Thomas" last="Ruhstaller">Thomas Ruhstaller</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Colleoni, Marco" sort="Colleoni, Marco" uniqKey="Colleoni M" first="Marco" last="Colleoni">Marco Colleoni</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Coates, Alan S" sort="Coates, Alan S" uniqKey="Coates A" first="Alan S." last="Coates">Alan S. Coates</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Goldhirsch, Aron" sort="Goldhirsch, Aron" uniqKey="Goldhirsch A" first="Aron" last="Goldhirsch">Aron Goldhirsch</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Price, Karen N" sort="Price, Karen N" uniqKey="Price K" first="Karen N." last="Price">Karen N. Price</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Gelber, Richard D" sort="Gelber, Richard D" uniqKey="Gelber R" first="Richard D." last="Gelber">Richard D. Gelber</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Regan, Meredith M" sort="Regan, Meredith M" uniqKey="Regan M" first="Meredith M." last="Regan">Meredith M. Regan</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author><author><name sortKey="Fleming, Gini F" sort="Fleming, Gini F" uniqKey="Fleming G" first="Gini F." last="Fleming">Gini F. Fleming</name><affiliation><nlm:aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</nlm:aff></affiliation></author></analytic><series><title level="j">Journal of Clinical Oncology</title><idno type="ISSN">0732-183X</idno><idno type="eISSN">1527-7755</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Purpose</title><p>The Suppression of Ovarian Function trial showed improved disease control for tamoxifen plus ovarian function suppression (OFS) compared with tamoxifen alone for the cohort of premenopausal patients who received prior chemotherapy. We present the patient-reported outcomes.</p></sec><sec><title>Patients and Methods</title><p>The quality-of-life (QoL) analysis includes 1,722 of 2,045 premenopausal patients with hormone receptor–positive breast cancer randomly assigned to receive adjuvant treatment with 5 years of tamoxifen plus OFS or tamoxifen alone. Chemotherapy use before enrollment was optional. Patients completed a QoL form consisting of global and symptom indicators at baseline, every 6 months for 24 months, and annually during years 3 to 6. Differences in the change of QoL from baseline between the two treatments were tested at 6, 24, and 60 months with mixed models for repeated measures with and without chemotherapy and overall.</p></sec><sec><title>Results</title><p>Patients on tamoxifen plus OFS were more affected than patients on tamoxifen alone by hot flushes at 6 and 24 months, by loss of sexual interest and sleep disturbance at 6 months, and by vaginal dryness up to 60 months. Without prior chemotherapy, patients on tamoxifen alone reported more vaginal discharge over the 5 years than patients on tamoxifen plus OFS. Symptom-specific treatment differences at 6 months were less pronounced in patients with prior chemotherapy. Changes in global QoL indicators from baseline were small and similar between treatments over the whole treatment period.</p></sec><sec><title>Conclusion</title><p>Overall, OFS added to tamoxifen resulted in worse endocrine symptoms and sexual functioning during the first 2 years of treatment, with variable magnitudes of treatment differences. Short-term differences in symptom-specific QoL, treatment burden, and coping effort between treatment groups were less pronounced for patients with prior chemotherapy, the cohort that benefited most from OFS in terms of disease control.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id><journal-id journal-id-type="hwp">jco</journal-id><journal-id journal-id-type="pmc">jco</journal-id><journal-id journal-id-type="publisher-id">JCO</journal-id><journal-title-group><journal-title>Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0732-183X</issn><issn pub-type="epub">1527-7755</issn><publisher><publisher-name>American Society of Clinical Oncology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27022111</article-id><article-id pub-id-type="pmc">4872319</article-id><article-id pub-id-type="publisher-id">648675</article-id><article-id pub-id-type="doi">10.1200/JCO.2015.64.8675</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>Bc7</subject><subject>Psc6</subject><subject>Psc13</subject></subj-group><subj-group subj-group-type="heading"><subject>ORIGINAL REPORTS</subject><subj-group><subject>Breast Cancer</subject></subj-group></subj-group></article-categories><title-group><article-title>Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial</article-title><alt-title alt-title-type="short">Patient-Reported Outcomes in the SOFT Trial</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ribi</surname><given-names>Karin</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Weixiu</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Bernhard</surname><given-names>Jürg</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Francis</surname><given-names>Prudence A.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Burstein</surname><given-names>Harold J.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Ciruelos</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Bellet</surname><given-names>Meritxell</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Pavesi</surname><given-names>Lorenzo</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Lluch</surname><given-names>Ana</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Visini</surname><given-names>Marilena</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Parmar</surname><given-names>Vani</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Tondini</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Kerbrat</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Perelló</surname><given-names>Antonia</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Neven</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Torres</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Lombardi</surname><given-names>Davide</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Puglisi</surname><given-names>Fabio</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Karlsson</surname><given-names>Per</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Ruhstaller</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Colleoni</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Coates</surname><given-names>Alan S.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Goldhirsch</surname><given-names>Aron</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Price</surname><given-names>Karen N.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Gelber</surname><given-names>Richard D.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Regan</surname><given-names>Meredith M.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Fleming</surname><given-names>Gini F.</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><aff id="aff1">Karin Ribi, Aron Goldhirsch, and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern; Thomas Ruhstaller, Breast Center St Gallen, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, St Gallen, Switzerland; Weixiu Luo, Karen N. Price, Richard D. Gelber, and Meredith M. Regan, International Breast Cancer Study Group Statistical Center; Weixiu Luo, Harold J. Burstein, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Harold J. Burstein, Alliance for Clinical Trials in Oncology; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber and Meredith M. Regan, Harvard Medical School, Boston, MA; Gini F. Fleming, The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL; Prudence A. Francis, International Breast Cancer Study Group, Peter MacCallum Cancer Center, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria; Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Eva Ciruelos, University Hospital 12 de Octubre and SOLTI Group, Madrid; Meritxell Bellet, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, and SOLTI Group, Universitat Autònoma de Barcelona, Barcelona; Ana Lluch, Hospital Clinico Universitario de Valencia, Incliva Biomedical Research Institute, University of Valencia and SOLTI Group, Valencia; Antonia Perelló, Hospital Universitari Son Espases and SOLTI Group, Palma de Mallorca, Spain; Lorenzo Pavesi, Salvatore Maugeri Foundation and International Breast Cancer Study Group, Pavia; Marilena Visini, Ospedale Civile di Lecco and International Breast Cancer Study Group, Lecco; Carlo Tondini, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo; Davide Lombardi, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano; Fabio Puglisi, University Hospital of Udine, University of Udine, and International Breast Cancer Study Group, Udine; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy; Vani Parmar, Breast Services, Tata Memorial Hospital and International Breast Cancer Study Group, Mumbai, India; Pierre Kerbrat, Centre Eugène Marquis, Université de Rennes 1, Rennes, France; Pierre Kerbrat and Patrick Neven, European Organisation for Research and Treatment of Cancer, Brussels; Patrick Neven, UZ Gasthuisberg, Leuven, Belgium; Roberto Torres, Instituto Nacional del Cancer, Chilean Cooperative Group for Oncologic Research Group, and International Breast Cancer Study Group, Santiago, Chile; and Per Karlsson, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, and International Breast Cancer Study Group, Gothenburg, Sweden.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Karin Ribi, PhD, International Breast Cancer Study Group Coordinating Center, Effingerstrasse 40, 3008 Bern, Switzerland; e-mail: <email>karin.ribi@ibcsg.org</email>.</corresp></author-notes><pub-date pub-type="ppub"><day>10</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>28</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>4</month><year>2017</year></pub-date><pmc-comment> PMC Release delay is 11 months and
0 days and was based on the
<volume>34</volume><issue>14</issue><fpage>1601</fpage><lpage>1610</lpage><permissions><copyright-statement>© 2016 by American Society of Clinical Oncology</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>American Society of Clinical Oncology</copyright-holder></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="JCO648675.pdf"></self-uri><abstract><sec><title>Purpose</title><p>The Suppression of Ovarian Function trial showed improved disease control for tamoxifen plus ovarian function suppression (OFS) compared with tamoxifen alone for the cohort of premenopausal patients who received prior chemotherapy. We present the patient-reported outcomes.</p></sec><sec><title>Patients and Methods</title><p>The quality-of-life (QoL) analysis includes 1,722 of 2,045 premenopausal patients with hormone receptor–positive breast cancer randomly assigned to receive adjuvant treatment with 5 years of tamoxifen plus OFS or tamoxifen alone. Chemotherapy use before enrollment was optional. Patients completed a QoL form consisting of global and symptom indicators at baseline, every 6 months for 24 months, and annually during years 3 to 6. Differences in the change of QoL from baseline between the two treatments were tested at 6, 24, and 60 months with mixed models for repeated measures with and without chemotherapy and overall.</p></sec><sec><title>Results</title><p>Patients on tamoxifen plus OFS were more affected than patients on tamoxifen alone by hot flushes at 6 and 24 months, by loss of sexual interest and sleep disturbance at 6 months, and by vaginal dryness up to 60 months. Without prior chemotherapy, patients on tamoxifen alone reported more vaginal discharge over the 5 years than patients on tamoxifen plus OFS. Symptom-specific treatment differences at 6 months were less pronounced in patients with prior chemotherapy. Changes in global QoL indicators from baseline were small and similar between treatments over the whole treatment period.</p></sec><sec><title>Conclusion</title><p>Overall, OFS added to tamoxifen resulted in worse endocrine symptoms and sexual functioning during the first 2 years of treatment, with variable magnitudes of treatment differences. Short-term differences in symptom-specific QoL, treatment burden, and coping effort between treatment groups were less pronounced for patients with prior chemotherapy, the cohort that benefited most from OFS in terms of disease control.</p></sec></abstract><counts><fig-count count="7"></fig-count><table-count count="3"></table-count><equation-count count="0"></equation-count><ref-count count="28"></ref-count><page-count count="22"></page-count></counts><custom-meta-group><custom-meta><meta-name> DJS Export </meta-name><meta-value>v1</meta-value></custom-meta></custom-meta-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0004639 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0004639 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |